About Affinium Pharmaceuticals
Affinium Pharmaceuticals is a Healthcare company based in Toronto (Canada) founded in 2000, and was acquired by Debiopharm in February 2014. Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm. Affinium Pharmaceuticals has raised $33 million across 3 funding rounds from investors including Debiopharm, Forward Ventures and Venture Ontario. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
Affinium Pharmaceuticals was a Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. As of February 11, 2014, Affinium Pharmaceuticals was acquired by Debiopharm Group. The company has a proprietary antibacterial platform that targets bacterial fatty acid synthesis. The company was developing AFN-1252, and its pro-drug, AFN-1720 for the oral and IV treatment of staphylococcal infections (tested on 5400 strains), including methicillin-resistant S. aureus (MRSA), and vancomycin-intermediate S. aureus (VISA). At the time of acquisition, AFN-1252 had completed a Phase 2a study for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and AFN-1720 was in Phase 1 clinical development. Affinium was previously called Integrative Proteomics, Inc.
- Headquarters Toronto, Canada
- Stage Acquired
- SectorsHealthcare
- Website afnm.com
- Acquired by Debiopharm (Feb 2014)
- Total Equity Funding$33M (USD)
in 3 rounds
- Latest Funding Round$18.9M (USD), Debt – Conventional
Sep 2013
- InvestorsDebiopharm
& 5 more
- Acquired byDebiopharm
(Feb 2014)
Funding Insights of Affinium Pharmaceuticals
Affinium Pharmaceuticals has successfully raised a total of $33M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $18.9 million completed in September 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33M
- Total Rounds 3
- Last Round Debt – Conventional — $18.9M
- First Round $18M
(Mar 2007)
- Investors Count 5
All 3 funding rounds of Affinium Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2013 | $18.9M | Debt – Conventional | – | – | – |
| Aug 2011 | $15M | Series B | – | Ontario Capital Growth Corporation | |
| Mar 2007 | $18M | Series A | – | Forward Ventures |
6 investors in total: 6 institutional.
Investors in Affinium Pharmaceuticals
Affinium Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Debiopharm, Forward Ventures and Venture Ontario.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
Venture capital investments are managed for Ontario's technology sector. | ocgc.gov.on.ca | Toronto, Canada | ||
Early-stage life sciences companies are supported through venture capital investments. | genesyscapital.com | Toronto, Canada | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs | 1979 | debiopharm.com | Lausanne, Switzerland |
Investor details for Affinium Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Affinium Pharmaceuticals
4 dated milestones of Affinium Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Affinium Pharmaceuticals is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Debt – Conventional, of $18.9M.
- Exit Acquired by Debiopharm.
Web traffic of Affinium Pharmaceuticals
Websites that share an audience with Affinium Pharmaceuticals (afnm.com).
Websites whose visitors overlap most with Affinium Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
aplagen.com | aplagen.com | 100% | – | ||
pxpharma.com | pxpharma.com | 100% | – | ||
| biotech-concepts.com | 100% | View details | |||
| ligand.com | 100% | 7K | #3,254,882 | View details | |
| serono.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Affinium Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Affinium Pharmaceuticals
Complete news archive for Affinium Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affinium Pharmaceuticals
Affinium Pharmaceuticals was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Affinium Pharmaceuticals is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Affinium Pharmaceuticals is a funded company, having raised a total of $33M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Mar 2007.
Affinium Pharmaceuticals was a Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. As of February 11, 2014, Affinium Pharmaceuticals was acquired by Debiopharm Group. The company has a proprietary antibacterial platform that targets bacterial fatty acid synthesis. The company was developing AFN-1252, and its pro-drug, AFN-1720 for the oral and IV treatment of staphylococcal infections (tested on 5400 strains), including methicillin-resistant S. aureus (MRSA), and vancomycin-intermediate S. aureus (VISA). At the time of acquisition, AFN-1252 had completed a Phase 2a study for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and AFN-1720 was in Phase 1 clinical development. Affinium was previously called Integrative Proteomics, Inc.
Affinium Pharmaceuticals has 6 investors. Key investors include Debiopharm, Forward Ventures, Venture Ontario, Genesys Capital, and SV Health Investors.
Yes. Affinium Pharmaceuticals was acquired by Debiopharm in February 2014.